21 CFR Part 700 - GENERAL

prev | next
{'United States Code': [{'Title': '21', 'Section': '321', 'headtext': ' Definitions; generally', 'cleanpath': '/uscode/text/21/321'}, {'Title': '21', 'Section': '348', 'headtext': ' Food additives', 'cleanpath': '/uscode/text/21/348'}, {'Title': '21', 'Section': '351', 'headtext': ' Adulterated drugs and devices', 'cleanpath': '/uscode/text/21/351'}, {'Title': '21', 'Section': '352', 'headtext': ' Misbranded drugs and devices', 'cleanpath': '/uscode/text/21/352'}, {'Title': '21', 'Section': '355', 'headtext': ' New drugs', 'cleanpath': '/uscode/text/21/355'}, {'Title': '21', 'Section': '355-1', 'headtext': ' Risk evaluation and mitigation strategies', 'cleanpath': '/uscode/text/21/355-1'}, {'Title': '21', 'Section': '355a', 'headtext': ' Pediatric studies of drugs', 'cleanpath': '/uscode/text/21/355a'}, {'Title': '21', 'Section': '355b', 'headtext': ' Adverse-event reporting', 'cleanpath': '/uscode/text/21/355b'}, {'Title': '21', 'Section': '355c', 'headtext': ' Research into pediatric uses for drugs and biological products', 'cleanpath': '/uscode/text/21/355c'}, {'Title': '21', 'Section': '355d', 'headtext': ' Internal committee for review of pediatric plans, assessments, deferrals, deferral extensions, and waivers', 'cleanpath': '/uscode/text/21/355d'}, {'Title': '21', 'Section': '355e', 'headtext': ' Pharmaceutical security', 'cleanpath': '/uscode/text/21/355e'}, {'Title': '21', 'Section': '356', 'headtext': ' Expedited approval of drugs for serious or life-threatening diseases or conditions', 'cleanpath': '/uscode/text/21/356'}, {'Title': '21', 'Section': '356-1', 'headtext': ' Accelerated approval of priority countermeasures', 'cleanpath': '/uscode/text/21/356-1'}, {'Title': '21', 'Section': '356a', 'headtext': ' Manufacturing changes', 'cleanpath': '/uscode/text/21/356a'}, {'Title': '21', 'Section': '356b', 'headtext': ' Reports of postmarketing studies', 'cleanpath': '/uscode/text/21/356b'}, {'Title': '21', 'Section': '356c', 'headtext': ' Discontinuance or interruption in the production of life-saving drugs', 'cleanpath': '/uscode/text/21/356c'}, {'Title': '21', 'Section': '357', 'headtext': ' Qualification of drug development tools', 'cleanpath': '/uscode/text/21/357'}, {'Title': '21', 'Section': '361', 'headtext': ' Adulterated cosmetics', 'cleanpath': '/uscode/text/21/361'}, {'Title': '21', 'Section': '362', 'headtext': ' Misbranded cosmetics', 'cleanpath': '/uscode/text/21/362'}, {'Title': '21', 'Section': '371', 'headtext': ' Regulations and hearings', 'cleanpath': '/uscode/text/21/371'}, {'Title': '21', 'Section': '374', 'headtext': ' Inspection', 'cleanpath': '/uscode/text/21/374'}, {'Title': '42', 'Section': '4332', 'headtext': ' Cooperation of agencies; reports; availability of information; recommendations; international and national coordination of efforts', 'cleanpath': '/uscode/text/42/4332'}], 'Statutes at Large': [], 'Public Laws': [], 'Presidential Documents': []}